Which biopsy method best spots aggressive prostate cancer? major trial launches
NCT ID NCT06303622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways to guide prostate biopsies using MRI: cognitive-guided (doctor mentally aligns images) and MRI-ultrasound fusion (computer overlays images). It aims to see which method finds more clinically significant prostate cancers. The trial will enroll 1,250 men with suspicious MRI lesions and a PSA under 20.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this trial could show which biopsy method is better at finding aggressive prostate cancers, helping doctors choose the most accurate approach.
- What could go wrong
- This is a diagnostic comparison study, not a treatment trial. It may not change outcomes directly, and results depend on the skill of the doctors performing the biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?